C. Alexander

发表

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

P. Harrigan, K. Hertogs, W. Verbiest, 1999, AIDS.

A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.

Julio S. G. Montaner, P. Harrigan, B. Yip, 2006, The Journal of infectious diseases.

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

P. Harrigan, C. Alexander, J. Montaner, 2002, The New England journal of medicine.

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2005, The Journal of infectious diseases.

Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.

C. Alexander, J. Montaner, M. O’Shaughnessy, 2002, AIDS.

Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART

P. Harrigan, B. Yip, R. Hogg, 2006, PLoS medicine.

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy

K. Hertogs, W. Verbiest, B. Larder, 2002, Antiviral therapy.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Simplification of Therapeutic Drug Monitoring for Twice-Daily Regimens of Lopinavir/Ritonavir for HIV infection

P. Harrigan, C. Alexander, J. Montaner, 2004, Therapeutic drug monitoring.

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.

P. Harrigan, C. Alexander, J. Montaner, 1999, AIDS.

HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort

Julio S. G. Montaner, Michael V. O'Shaughnessy, P. Harrigan, 2001, AIDS.

Selection of drug-resistant HIV.

C. Alexander, P. R. Harrigan, 1999, Trends in microbiology.

Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.

P. Harrigan, C. Alexander, J. Montaner, 2000, The Journal of infectious diseases.

Prevalence and Response to Antiretroviral Therapy of Non-B Subtypes of HIV in Antiretroviral-Naive Individuals in British Columbia

P. Harrigan, C. Alexander, J. Montaner, 2002, Antiviral therapy.

Are untimed antiretroviral drug levels useful predictors of adherence behavior?

P. Harrigan, C. Alexander, D. Bangsberg, 2003, AIDS.